Table 2.
Oncological outcomes of the combination of durvalumab plus tremelimumab in comparison with other treatments in patients affected by lung cancers or malignant mesothelioma
| Author [References] | Value (95% CI) | Treatments | Comment | |||
|---|---|---|---|---|---|---|
| D+T | ||||||
| Antonia et al. [14] | AE | 36% |
Single-arm study Immunotherapy-naïve patients |
|||
| D | D+T | C | ||||
| Rizvi et al. [15] | OS m | 16.3 | 11.9 | 12.9 |
MYSTIC trial First-line treatment |
|
| PFS m | 4.7 | 3.9 | 5.4 | |||
| ORR % | 35.60% | 34.40% | 37.70% | |||
| Study A | Study B | |||||
| D | SoC | D+T | SoC | |||
| Planchard et al. [17] | OS m | 11.7 | 6.8 | 11.5 | 8.7 |
ARCTIC trial Third-line treatment Study A: PDL-1 TC ≥ 25% Study B: PDL-1 TC < 25% |
| PFS m | 3.8 | 2.2 | 3.5 | 3.5 | ||
| AE | 9.70% | 44.40% | 22.00% | 36.40% | ||
| D+T+PE | D+PE | PE | ||||
| Goldman et al. [18] | OS m | 10.4 | 12.9 | 10.5 |
CASPIAN trial First-line treatment |
|
| PFS m | 4.9 | 5.1 | 5.4 | |||
| D+T | SBRT | |||||
| Pakkala et al. [19] | ORR | 0% | 28.60% | More than 2 previous chemotherapy lines | ||
| PFS m | 2.1 | 3.3 | ||||
| OS m | 2.8 | 5.7 | ||||
| D+T | ||||||
| Calabrò et al. [20] | PFS m | 5.7 |
NIBIT-MESO-1 trial Single-arm study First-line treatment |
|||
| OS m | 16.6 | |||||
| AE | 75% | |||||
| D+T | ||||||
| Kim et al. [21] | PFS m | 5.9 |
Single-arm study First-line treatment |
|||
| OS m | 15.4 | |||||
AE treatment-related adverse events, C chemotherapy, CI confidence interval, D durvalumab, ORR objective response rate, OS m median overall survival, PDL-1 TC tumor cell programmed cell death ligand 1, PE platinum-etoposide, PFS m median progression-free survival, SBRT stereotactic body radiation therapy, SoC standard of care, T tremelimumab